David Shook - 15 Jan 2025 Form 4 Insider Report for Nkarta, Inc. (NKTX)

Reporting relationship: Chief Medical Officer, Head of Research & Development
Issuer ticker: NKTX
Reported as of: 15 Jan 2025
Net transaction value: -$19,004
SEC form: 4
Accepted by SEC: 17 Jan 2025, 17:37:19 UTC
Prior SEC filing: 07 Jan 2025
Next SEC filing: 11 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Alicia Hager, as Attorney-in-Fact

Key filing fact

David Shook filed Form 4 for Nkarta, Inc. (NKTX) on 17 Jan 2025.

Key facts

This page summarizes David Shook's Form 4 filing for Nkarta, Inc. (NKTX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 17 Jan 2025, 17:37.

Change

Previous filing in this sequence was filed on 07 Jan 2025.
Current net transaction value: -$19,004.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NKTX transaction

Common Stock

Sale

Transaction value: $19,004
Shares: -8,638
Change %: -4.3%
Price: $2.20
Shares after: 190,955
Date: 15 Jan 2025
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents shares sold as required by the applicable award terms to satisfy tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units and does not represent a discretionary transaction by the Reporting Person.

SEC remarks

Chief Medical Officer, Head of Research & Development